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Ferritin levels in the cerebrospinal fluid predict
Alzheimer’s disease outcomes and are regulated
by APOE
Scott Ayton1,*, Noel G. Faux2,3,*, Ashley I. Bush1,3 & Alzheimer’s Disease Neuroimaging Initiativew
Brain iron elevation is implicated in Alzheimer’s disease (AD) pathogenesis, but the impact of
iron on disease outcomes has not been previously explored in a longitudinal study. Ferritin is
the major iron storage protein of the body; by using cerebrospinal fluid (CSF) levels of ferritin
as an index, we explored whether brain iron status impacts longitudinal outcomes in the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. We show that baseline CSF
ferritin levels were negatively associated with cognitive performance over 7 years in 91
cognitively normal, 144 mild cognitive impairment (MCI) and 67 AD subjects, and predicted
MCI conversion to AD. Ferritin was strongly associated with CSF apolipoprotein E levels and
was elevated by the Alzheimer’s risk allele, APOE-e4. These findings reveal that elevated brain
iron adversely impacts on AD progression, and introduce brain iron elevation as a possible
mechanism for APOE-e4 being the major genetic risk factor for AD.
DOI: 10.1038/ncomms7760 OPEN
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C
ortical iron elevation is increasingly reported as a feature
of Alzheimer’s disease (AD)1, and might contribute to the
oxidative damage observed in AD brains2. A single-blind,
2-year trial of 48 AD patients with the iron chelator,
deferoxamine, reported decreased cognitive decline3, but this
has not been followed up. While evidence in animal models argue
in favour of brain iron accumulation propelling atrophy and
dementia4, prospective evidence about the link between brain
iron status and clinical outcomes in AD is lacking.
CSF ferritin could be an index of brain iron load. Ferritin is the
iron storage protein of the body and is elevated in AD brain
tissue5–8. In cultured systems, ferritin expression9,10 and
secretion11 by glia is dependent on cellular iron levels. Ferritin
levels in CSF likely reflect iron levels in the brain and can have
clinical utility. For example, in Restless Legs Syndrome, a disorder
of low brain iron that is treated with iron supplementation, CSF
ferritin levels are decreased12. CSF ferritin was reported to be
elevated in AD in one study13, but this was not repeated in
subsequent studies using larger clinical cohorts14,15.
Here, we examined the association of baseline CSF-ferritin data
with biomarker, cognitive, anatomical and diagnostic outcomes
over 7 years in the Alzheimer’s disease Neuroimaging Initiative
(ADNI) prospective clinical cohort. We show that CSF ferritin
levels have similar utility compared with more established AD
CSF biomarkers, the tau/Ab1–42 ratio and apolipoprotein E
(ApoE) levels, in predicting various outcomes of AD. However,
the nature of the relationship between CSF ferritin levels and
cognitive performance was different from the other biomarkers,
and, in contrast, CSF ferritin appears as a trait variable, and not a
marker of disease.
Results
The relationship between CSF ferritin and biomarkers of AD.
In agreement with other reports14,15, CSF ferritin levels were not
different between cognitively normal (CN; n¼ 91), mild cognitive
impairment (MCI; n¼ 144) and AD (n¼ 67) subjects
(ANCOVA: P¼ 0.591; Table 1) in the ADNI cohort. Neither
were there changes in ferritin levels when we separated the cohort
according to CSF Ab1–42 levels (192 ng l 1 cutoff; as proposed
previously16) to reflect likely cerebral amyloid burden
(ANCOVA: P¼ 0.946; Supplementary Fig. 1). But in multiple
regression modelling of ferritin including the established CSF
biomarkers of AD17 (tau, p-tau, Ab1–42), CSF ferritin levels were
predicted by Ab1–42 (partial R2¼ 0.013, P¼ 0.029) and tau
(partial R2¼ 0.086, Po0.001; model 1, Supplementary Table 1),
although not by p-tau. Since the apolipoprotein E gene
(APOE) alleles are the major genetic risk for AD18 and CSF
apolipoprotein E protein (ApoE) levels are associated with
Ab1-42 (refs 19,20) and tau20,21, we re-built the model to
include CSF ApoE levels. This abolished the relationship
between ferritin and the other biomarkers (Ab1–42: R2o0.001,
P¼ 0.904; tau: R2¼ 0.003, P¼ 0.219; model 2, Supplementary
Table 1). This led us to detect a surprisingly strong relationship
between ApoE and ferritin (linear term partial R2¼ 0.243,
P¼ 7.69 10 22), which was improved when Ab1–42 and tau
Table 1 | Baseline characteristics of subjects from the ADNI cohort used in this study, stratified by diagnosis.
Units CN MCI AD P-value
n — 91 144 67 NA
Age Years (s.d.) 75.74 (5.43) 74.85 (7.2) 74.57 (7.61) 0.502
Female n (%) 46 (50.55) 47 (32.64) 29 (43.28) 0.021
Education Years (s.d.) 15.67 (2.94) 15.91 (2.95) 15.01 (2.96) 0.123
APOE-e4 þ ve n (%) 22 (24.18) 75 (52.08) 46 (68.66) 6.50 10 8
ADAS-Cog13 Units (s.d.) 9.51 (4.16) 19.19 (5.94) 29.22 (8.21) 2.75 10 56
CSF Ferritin ngml 1 (s.d.) 6.4 (2.07) 6.95 (2.72) 6.94 (2.99) 0.591
CSF ApoE mgml 1 (s.d.) 7.3 (2.21) 7.1 (2.22) 6.35 (2.27) 0.012
CSF tau pgml 1 (s.d.) 69.78 (28.01) 104.3 (52.41) 122.63 (57.47) 4.57 10 7
CSF ptau pgml 1 (s.d.) 24.77 (13.34) 36.39 (16.09) 41.39 (20.76) 1.13 10 6
CSF Ab1-42 pgml 1 (s.d.) 205.31 (56.38) 161.06 (52.06) 142.16 (36.84) 2.29 10 6
CSF tau/Ab1–42 Units (s.d.) 0.39 (0.26) 0.75 (0.5) 0.94 (0.52) 7.80 10 9
Hippocampus mm3 (s.d.) 7,219.6 (848.6) 6,230.9 (1,047.8) 5.766.6 (1,283.2) 6.71 10 20
Lateral ventricle mm3 (s.d.) 34,052.62 (16,528.1) 44,842.52 (23,574.05) 49,902.53 (26,896.68) 3.35 10 5
AD, Alzheimer’s disease; CN, cognitively normal; CSF, cerebrospinal fluid; MCI, mild cognitive impairment. Unadjusted unit values are presented in the table. P values presented for ANCOVA models of
CSF analytes and MRI brain structure were adjusted for age, gender, years of education, BMI, APOE genotype, CSF haemoglobin and CSF Factor H. Intracranial volume was also included in ANCOVA
models of brain structure.
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Figure 1 | CSF ferritin associates with ApoE levels and varies according
to APOE genotype. (a,b) Modelling ferritin in CSF (refer to, M3 of
Supplementary Table 1). Minimal multiple regression contained CSF ApoE
and APOE e4. (a) Scatterplot of CSF ApoE and ferritin levels in APOE e4
carriers and non-e4 carriers. The genotype did not affect the relationship
between ApoE and ferritin; however, genotype is associated with CSF
ferritin levels, and thus e4 carriers and non-e4 carriers are plotted
separately. The R2 for the linear component of the full model was 0.341
(displayed on graph). (b) CSF Ferritin levels in APOE e4 carriers and non-
carriers (ANCOVA: P-value¼ 1.10 108). (c) Multiple regression of CSF
ApoE. ApoE levels in APOE e4 carriers and non-carriers (ANCOVA:
P¼ 2.50 109). Data are meansþ s.e. ‘n’ is represented in graph
columns.
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(non-significant terms) were removed from the model (linear
term partial R2¼ 0.341, P¼ 1.52 10 29; model 3,
Supplementary Table 1, Fig. 1a).
In model 3, APOE genotype strongly influenced CSF ferritin
(P¼ 1.10 10 8), with the major AD risk allele, e4, inducing
22% higher levels than non-e4 carriers (Fig. 1b). Reciprocally, in
multiple regression modelling of CSF ApoE, APOE e4-positive
subjects had lower ApoE levels (-16%; P¼ 2.50 10 9)
compared with non-e4 carriers (Fig. 1c). Plasma ferritin levels
were not associated with plasma ApoE levels or APOE e4 allele
status (Supplementary Fig. 2), but there was a modest association
between plasma ferritin and CSF ferritin levels (b¼ 0.075,
P¼ 0.0002; Supplementary Fig. 3).
Association of ferritin with neuropsychiatric assessments.
Next, we explored whether CSF ferritin was related to cognitive
performance in AD. Baseline ADAS-Cog13 (The Alzheimer’s
Disease Assessment Scale) score was associated with CSF ferritin
(P¼ 0.006; Table 2), ApoE levels (P¼ 0.0003) and tau/Ab1–42
ratio (P¼ 0.025), independently, in a multiple regression model
containing the AD biomarkers and other clinical variables.
In tertile analysis, high (47.2 ngml 1), compared with low
(o5.4 ngml 1), levels of ferritin were associated with an E3
point poorer ADAS-cog13 score (Fig. 2a). Similarly, in tertiles,
lower levels of ApoE (Fig. 2b) were associated with a E4 point
worse ADAS-Cog13, and higher tau/Ab1-42 ratio was associated
with a E2 point worse ADAS-Cog13 (Fig. 2c), as previously
reported21,22.
To determine whether baseline values of CSF ferritin predict
longitudinal cognitive outcome, we constructed a mixed effects
model of annual ADAS-Cog13 scores over 7 years (Table 2 for
statistics, Supplementary Table 2 for patient numbers) and
observed that both ApoE (P¼ 0.006) and tau/Ab1-42 ratio
Table 2 | Modelling the association of CSF biomarkers on AD outcomes.
Model Ferritin* tau/Ab1–42 ApoE
Cross-sectional cognition (MR) b (s.e.) P value b (s.e.) P value b (s.e.) P value
ADAS-Cog13w 0.139 (0.050) 0.006 0.104 (0.046) 0.025 0.178 (0.049) 0.0003
RAVLT  1.77 (0.559) 0.0017 NS NS 1.033 (0.564) 0.0677
Longitudinal cognition (MELM) b (s.e.) P value b (s.e.) P value b (s.e.) P value
ADAS-Cog13w
Main effect 0.178 (0.051) 0.0005 0.129 (0.049) 0.009 0.180 (0.051) 0.0004
Interaction time 0.0005 (0.016) 0.977 0.081 (0.016) 2.70 10 7 0.044 (0.016) 0.006
RAVLT
Main effect  1.60 (0.63) 0.012 0.847 (0.608) 0.165 1.03 (0.63) 0.104
Interaction time 0.035 (0.152) 0.817 0.610 (0.150) 4.85 10 5 0.279 (0.152) 0.066
MCI conversion to AD Statisticz P value Statisticz P value Statisticz P value
Cox (Hazard ratio) 1.10 (1.01–1.19) 0.030 1.53 (1.03–2.28) 0.037 0.83 (0.73–0.95) 0.008
LR (Odds ratio) 2.32 (1.86–2.90) 8.001 10 15 1.45 (1.16–1.80) 0.0001 0.38 (0.30–0.48) 1.88 10 17
Rate of MRI atrophy (MELM) b (s.e.) P value b (s.e.) P value b (s.e.) P value
Hippocampus  18.33 (7.86) 0.019  35.31 (7.79) 6.81 10 6 21.38 (8.02) 0.008
Lateral ventriclesy 0.007 (0.003) 0.008 0.013 (0.002) 4.19 10 8 0.009 (0.003) 0.0002
Cox, Cox proportional hazard model; LR: logistic regression; MELM, mixed effects linear model; MR, multiple regression; NS, not significant. All models initially contained the variables: age, gender, BMI,
APOE genotype, baseline diagnosis; the MRI models additionally included intracranial volume. Minimal models for the cognition models included baseline diagnosis, gender, years of education and the AD
CSF biomarkers. Minimal model for the Cox proportional hazard model (Cox) contained only the AD CSF biomarkers. Minimal models for the MRI models contained age, gender, baseline diagnosis, years
of education, APOE e4 status and intracranial volume. All subjects with available data were included in the cross-sectional cognition models. Only CN and MCI subjects were included in modelling of
longitudinal cognition because short follow up of AD subjects (Supplementary Table 3). Only subjects who were classed as MCI at baseline were included in the MCI conversion models. The MRI models
contained subjects who were classed as cognitively normal or MCI at baseline. AD subjects at baseline were not included because of low numbers and lack of follow-up (Supplementary Tables 3).
*Ferritin values were log-transformed, excluding non-parametric Cox and LR models.
wThe b-coefficient is for the square root of ADAS-Cog13.
zThe statistics for the conversion models were based on one interquartile range change for each analyte (ferritin: 3.3 ngml 1, tau/Ab1–42: 0.67 units; ApoE: 3.1mgml 1).
yFor Lateral ventricles, the b-coefficient is for natural log of the ventricle volume.
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Figure 2 | CSF ferritin levels independently predict cognitive status.
(a–c) Multiple regression of baseline ADAS-Cog13 score expressed as
tertiles of CSF (a) ferritin (Lo5.5; H47.3 ngml 1), (b) ApoE (Lo 5.8;
H47.8 mgml 1) and (c) tau/Ab1–42 (Lo0.35; H40.76). (d) Multiple
regression of baseline RAVLT score expressed as CSF ferritin tertiles. Data
are adjusted for baseline diagnosis, gender, years of education and the AD
CSF biomarkers in the minimal models. Data are meansþ s.e. ‘n’ is shown in
graph columns. CN, cognitively normal; MCI, mild cognitive impairment.
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(P¼ 2.70 10 7) were still associated with rate of cognitive
change (interacted with time), as previously reported21,22.
Ferritin, however, impacted on ADAS-Cog13 by a constant
cross-sectional decrement (P¼ 4.93 10 4 main effect only;
Table 2).
We additionally modelled cognition using the Rey verbal
learning test (RAVLT), which is more sensitive in distinguishing
control and MCI patients23. In this model, only ferritin levels
were associated with cross-sectional cognitive performance
(P¼ 0.0017; Table 2, Fig. 2d), but CSF ferritin was not
associated with rate of deterioration in a longitudinal model
(P¼ 0.817; Table 2). Baseline tau/Ab1–42 ratio was associated with
rate of cognitive decline on RAVLT (P¼ 4.8510 10 5), but
there was only a trend for ApoE (P¼ 0.066). Hence, in both
cognitive scales, CSF ferritin impacted on performance by a
constant amount, regardless of disease status, thus appearing as a
trait variable and not a marker of disease.
We reasoned that if high ferritin levels worsened the cognitive
performance by a constant value over time, then MCI individuals
with high ferritin levels would satisfy the criteria for an AD
diagnosis at a comparatively earlier interval. To investigate this,
we employed a Cox proportional hazards model on 144 MCI
subjects who had CSF ferritin, ApoE and tau/Ab1-42 measure-
ments. In a minimal model (containing only these CSF
biomarkers; Table 2) of MCI conversion over 7 years, ferritin
(P¼ 0.03; Fig. 3a), ApoE (P¼ 0.008; Supplementary Fig. 4a) and
tau/Ab1–42 (P¼ 0.037; Supplementary Fig. 4b) were each
significant predictive variables.
Using this model we estimated how many months was required
for 50% survivorship for each quintile of each biomarker. We then
constructed a linear model of these values (in months; y-axis)
against the values for the quintile boundaries of each analyte (in
designated units; x-axis). The gradient of these functions estimates
the change in mean age of conversion (in months) associated with
one unit change in the baseline CSF analyte. For comparison
between biomarkers, we also expressed the change in mean age of
conversion associated with a s.d. change to the analyte value. One
s.d. change to ferritin was associated with a 9.5-month shift in age
of conversion, compared with 18.2 and 8.6 months for ApoE and
tau/Ab1–42, respectively (Fig. 3b).
In separate adjusted logistic regression models, an increase in
the baseline concentration of each biomarker by its interquartile
range increased the odds of converting to AD for ferritin
(OR: 1.36, 95%CI: 1.17–1.58) and tau/Ab1–42 ratio (OR: 1.13, CI:
0.95–1.35), and decreased the odds for ApoE (OR: 0.72, CI: 0.61–
0.85). Including all three analytes into the one model increased the
predictive value of each analyte (OR (CI): ferritin¼ 2.32 (1.86–2.9],
tau/Ab1–42¼ 1.45[1.16–1.8], ApoE¼ 0.38[0.3–0.48]; Table 2).
Receiver-operating curves based on the logistic regression
models determined the accuracy of these analytes to predict
conversion to AD. The area under the curve (AUC) of the base
model (age, gender, years of education, BMI, APOE e4 genotype)
was 0.6079 (Fig. 3c), which was increased by the singular
inclusions of either ferritin (AUC: 0.6321; Supplementary
Fig. 5b), ApoE (0.6311; Supplementary Fig. 5c) or marginally
by tau/Ab1–42 (0.6177; Supplementary Fig. 5d). When the
tau/Ab1–42 was included in the model containing ApoE, the
AUC increased slightly (from 0.6311 to 0.6483; Fig. 3d). This
performance, which combined the established CSF biomarkers
for AD, was improved markedly by adding ferritin values (from
0.6483 to 0.6937 Fig. 3e).
Association of ferritin with brain atrophy. Finally, we investi-
gated whether ferritin levels associate with neuroanatomical
changes to the hippocampus and lateral ventricular area in yearly
intervals over a 6-year period for CN and MCI subjects
(Supplementary Table 3 for patient numbers). We explored the
impact of CSF ferritin when the other biomarkers were also
included in modelling, whereas CSF ferritin has previously been
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shown to predict atrophy of various brain structures when con-
sidered in isolation24. Baseline ApoE, ferritin and tau/Ab1–42
values each independently predicted hippocampal volume in an
adjusted longitudinal model (Table 2). The rate of atrophy of the
hippocampus was greater in individuals with high CSF ferritin
(P¼ 0.02; Fig. 4a). Low CSF ApoE (P¼ 0.008; Fig. 4b) or high
tau/Ab1–42 (P¼ 6.80 10 6; Fig. 4c) also predicted atrophy, as
previous reported21,25. Lateral ventricular enlargement over time
was similarly associated independently with high-CSF ferritin
(P¼ 0.008; Fig. 4d), low-CSF ApoE (P¼ 0.0002; Fig. 4e), or high
tau/Ab1–42 (P¼ 4.19 10 8; Fig. 4f).
Discussion
Our analyses show that CSF ferritin levels were independently
related to cognitive performance in the ADNI cohort and
predicted MCI conversion to AD. The magnitude impact of
ferritin on these outcomes was comparable to the established
biomarkers, ApoE and tau/Ab1–42; however, the nature of the
effect of ferritin was not the same. Ferritin was associated with
constant shift in cognitive performance over the study period
(Fig. 5a), whereas the decrements associated with the other
biomarkers were exaggerated over time (Fig. 5b). A downward
shift (poorer cognitive presentation) in response to high ferritin
levels (1.77 RAVLT points per 1 ngml 1 ferritin; Table 2) results
in an earlier age of diagnosis (3 months per 1 ngngml 1 ferritin;
Fig. 3b). This would be consistent with findings that patients with
an early age of AD onset have greater neocortical iron burden
than late-onset patients1,7. Collectively these data support
consideration of therapeutic strategies that lower brain iron,
which have reported beneficial outcomes in Phase II trials of
Alzheimer’s3 and Parkinson’s26 diseases. Lowering CSF ferritin,
as might be expected from a drug like deferiprone26, could
conceivably delay MCI conversion to AD by as much as 3 years.
An unresolved question arising from this study is why are CSF
ferritin levels not elevated in AD, where brain iron levels are
reported as elevated2? We hypothesize that ferritin levels in the
CSF reflect global brain iron burden, whereas iron elevation in
AD has only been reported in affected regions (for example,
frontal cortical tissue27). Possibly, iron elevation in brain regions
affected by AD is too confined regionally to be reflected in CSF.
An altered relationship between tissue and CSF ferritin in AD,
however, cannot yet be excluded.
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ventricular changes based on CSF (d) ferritin (e) ApoE and (f) tau/Ab1–42 tertiles (refer to Table 2). These mixed effects models were adjusted for age,
gender, baseline diagnosis, years of education, APOE e4 status and intracranial volume. Tertiles at baseline were not significantly different for all models,
therefore for visual display the baseline values were held at the adjusted means for each diagnostic group. CN, cognitively normal; H, highest tertile; M,
middle tertile; MCI, mild cognitive impairment; L, lowest tertile.
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Figure 5 | Schematic: the impact of ferritin and other biomarkers on AD
presentation. (a) CSF ferritin has a qualitatively different impact to
(b) CSF tau/Ab1–42 and ApoE on cognitive performance over time in
cognitively normal (dotted lines) and in subjects who develop AD
(solid lines). Higher CSF ferritin levels are associated with poorer baseline
cognitive status (for example, RAVLT) by [a] points, where [a]¼ Ln[ferritin
(ngml 1)]*1  77 (refer to Table 2). This effect is constant over time,
such that [a]¼ [b,w]. Consequently, ferritin causes a shift to the left in
age of conversion to AD by [d] months, where [d]¼ ferritin (ngml 1)*3
(refer to Fig. 3b). Levels of tau/Ab1–42 or ApoE are associated with
both baseline cognitive status [e] and the rate of cognitive deterioration,
such that [e]o[f,g]. The effect causes a shift in age of diagnosis
by [Z] months where [Z]¼ApoE (mgml 1)*8 or tau/Ab1–42 (units)*17
(refer to Fig. 3b).
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Our data also provide exploratory insights into iron in AD
aetiopathogenesis, identifying an unexpected interaction of ApoE
with ferritin. That ferritin levels are increased by the APOE-e4
allele argues that ApoE influences ferritin levels, rather than the
reverse. Our current findings indicate that APOE genotype should
influence constitutive brain iron burden. However, to our knowl-
edge, a post mortem study of iron or ferritin in brain tissue,
stratified according to APOE genotype, has not been reported.
Focal changes to iron and ferritin have been observed in AD brains
post mortem1,2,5–8, and on the basis of our findings we propose
that the e4 genotype raises the baseline iron load of the brain, thus
lowering the threshold for iron-mediated neuronal loss in disease.
This proposal awaits experimental confirmation, but it is possible
that increased plaque pathology associated with the APOE e4
isoform28 might be a consequence of interactions between Ab and
iron29, leading to oxidative stress and Ab aggregation12,13. Elevated
iron could likewise contribute to tau pathology by causing its
aggregation30, indeed iron is co-localized in neurofibrillary tangles
in AD, and such co-localization is also observed in a primary
disease of brain iron overload, neurodegeneration with brain iron
accumulation2,31. Superficial CNS siderosis is also characterized by
brain iron deposition, and tau is elevated in the CSF in this
condition32. A relationship between brain iron and tau is
supported by the results in our study, where CSF ferritin levels
correlated with tau levels (Model 1 of Supplementary Table 1;
when ApoE is excluded from the analysis).
How, then, could ApoE impact on brain iron homeostasis? To
our knowledge, no previous study has directly explored this, but
synaptic zinc was reported to be lowered in APOE KO mice,33
and in a closed head injury model, iron accumulation was shown
to be exaggerated in APOE-KO mice34. The mechanism for ApoE
in iron regulation could involve the trafficking of lipoproteins by
ApoE. Treatment of macrophages with high-density lipoprotein
(HDL; the lipoprotein of CSF) has been shown to lower
intracellular iron levels and to promote ferritin release35. APOE
e4 carriers have less CSF ApoE, and the e4 isoform has
comparatively lower affinity for HDL36, so reduced delivery of
HDL in APOE e4 carriers could result in iron retention in the
brain. Notably, the iron accumulation mutation of HFE
(associated with hemochromatosis) has an epistatic interaction
with APOE e4 to increase AD risk and accelerates disease onset by
5.5 years (reviewed in ref. 37). We therefore introduce the
concept that APOE e4 status confers susceptibility to AD by
increasing ferritin levels. The association between ApoE and brain
iron status will warrant further investigation.
Methods
ADNI description. Data used in the preparation of this article were downloaded
on 15 July 2014 from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (adni.loni.usc.edu). The ADNI study has been previously described in
detail38. The ADNI was launched in 2003 by the National Institute on Aging
(NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB),
the Food and Drug Administration (FDA), private pharmaceutical companies and
non-profit organizations, as a $60 million, five-year public-private partnership. The
primary goal of ADNI has been to test whether serial magnetic resonance imaging
(MRI), positron emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression
of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).
Determination of sensitive and specific markers of very early AD progression is
intended to aid researchers and clinicians to develop new treatments and monitor
their effectiveness, as well as lessen the time and cost of clinical trials.
The principal investigator of this initiative is Michael W. Weiner, MD, VA
Medical Center and University of California, San Francisco. ADNI is the result of
efforts of many co-investigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from over 50 sites across the
United States and Canada. The initial goal of ADNI was to recruit 800 subjects but
ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols
have recruited over 1,500 adults, ages 55 to 90, to participate in the research,
consisting of cognitively normal older individuals, people with early or late MCI,
and people with early AD. The follow-up duration of each group is specified in the
protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for
ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date
information, see www.adni-info.org.
Recruitment inclusion and exclusion criteria for ADNI 1. Inclusion criteria were
as follows: (1) Hachinski Ischaemic Scorer4; (2) permitted medications stable for
4 weeks before screening; (3) Geriatric Depression Scale scoreo6; (4) visual and
auditory acuity adequate for neuropsychological testing; good general health with
no diseases precluding enrolment; (5) six grades of education or work history
equivalent; (6) ability to speak English or Spanish fluently; (7) a study partner with
10 h per week of contact either in person or on the telephone who could accom-
pany the participant to the clinic visits.
Criteria for the different diagnostic groups are summarized in Supplementary
Table 1. Groups were age-matched. Cognitively normal (CN) subjects must have
no significant cognitive impairment or impaired activities of daily living. Clinical
diagnosed AD patients must have had mild AD and had to meet the National
Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association criteria for probable AD39, whereas
mild cognitive impairment subjects (MCI) could not meet these criteria, have
largely intact general cognition as well as functional performance, but meet defined
criteria for MCI.
CSF biomarker collection and analysis. CSF was collected once in a subset of
ADNI participants at baseline. Ab1–42 and tau levels in CSF were measured using
the Luminex platform. ApoE and ferritin protein levels were determined using a
Myriad Rules Based Medicine platform (Human Discovery MAP, v1.0; see ADNI
materials and methods). CSF Factor H (FH) levels were measured using a multiplex
human neurodegenerative kit (HNDG1-36K; Millipore, Billerica, MA) according to
the manufacturer’s overnight protocol with minor modifications.
CSF was collected into polypropylene tubes or syringes provided to each site,
and then be transferred into polypropylene transfer tubes without any
centrifugation step followed by freezing on dry ice within 1 h after collection for
subsequent shipment overnight to the ADNI Biomarker Core laboratory at the
University of Pennsylvania Medical Center on dry ice. Aliquots (0.5ml) were
prepared from these samples after thawing (1 h) at room temperature and gentle
mixing. The aliquots were stored in bar code-labelled polypropylene vials at
 80 C. Fresh, never before thawed, 0.5ml aliquots for each subject’s set of
longitudinal time points were analysed on the same 96-well plate in the same
analytical run for this study to minimize run to run and reagent kit lot sources of
variation. Within run coefficient of variation (%CV) for duplicate samples ranged
from 2.5 to 5.9% for Ab1–42, 2.2–6.3% for tau and the inter-run %CV for CSF pool
samples ranged from 5.1 to 14% for Ab1–42, 2.7–11.2% for tau.
Apolipoprotein E (ApoE) and ferritin protein levels were determined using
Rules Based Medicine (Human Discovery MAP, v1.0).
Further information on the procedures and standard operating procedures can
be found in previous publications40,41 and online (http://www.adni-info.org/).
Structural MRI acquisition and processing. Subjects with a 1.5-T MRI and a
sagittal volumetric 3D MPRAGE with variable resolution around the target of
1.2mm isotropically were included in the analysis. See (www.loni.ucla.edu/ADNI)
and for detail42. The hippocampal and ventral volumes utilized were those in the
ADNIMERGE primary table as part of the ADNIMERGE R package, downloaded
on the 15 July 2014. Only CN and MCI subjects were included in the MRI analysis.
MRI scans were performed at baseline, 6 months, 1 year and then yearly for
six years.
Statistical analysis. All statistical work was conducted with R (version 3.1.0)43,
using packages ggplot2 (ref. 44), nlme45, car46 and Deducer47. We tested the
conditions necessary to apply the regression models, normal distribution of the
residuals and the absence of multicolinearity. All models satisfied these conditions.
Minimal models were obtained via step down regression using Akaike information
criterion (AIC), and Bayesian information criterion (BIC), ensuring that the central
hypotheses were maintained. Subjects were excluded from analysis if they had one
or more covariates missing. Where subjects prematurely left the study, their data
were included in modelling to the point at which they left. The following variables
were natural log-transformed to ensure normality: CSF ferritin, Factor H, tau and
haemoglobin, while ADAS-cog13 was square-root transformed.
ANCOVA models assessing the differences in each of the CSF biomarkers
across the diagnostic groups initially contained age, gender, BMI, APOE genotype,
and levels of CSF haemoglobin (Hb) and Factor H (FH). CSF Hb was included as a
proxy for blood contamination, to control for the possibility of a traumatic tap
introducing plasma ferritin into the CSF samples. FH was used to control for
inflammation, since ferritin levels are known to be elevated in certain inflammatory
conditions (for example, bacterial meningitis48).
Multiple regression models of CSF ferritin and ApoE initially contained age,
gender, BMI, APOE genotype, and levels of CSF Hb and FH, plus various
inclusions of CSF tau, Ab1–42 and either ferritin or ApoE. The minimal models are
described in the table legend.
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Associations between the baseline Alzheimer’s Disease Assessment Scale
Cognition (ADAS-cog13) and Rey Auditory Verbal Learning Test (RAVLT) scores
with CSF ferritin, the CSF tau/Ab1–42 ratio and CSF ApoE were tested with a
covariate-adjusted multiple regression for each cogntive scale. For these analyses,
age, gender, BMI, years of education, APOE-e4 allele and baseline diagnosis were
initially included as covariates. To assess the association of baseline CSF ferritin
levels with the longitudinal clinical outcomes (ADAS-cog13 and RAVLT scores
over 7 years), linear mixed effects models were used. These models were adjusted
for the same variables as the baseline models of cognition, and additionally
included time as interacting variable with each of the CSF biomarkers. AD subjects
were excluded from the longitudinal analysis because of low rate of follow up
(Supplementary Table 2). A significant value for any of these interaction terms
would indicate that the variable affected the rate of cognitive change. For the
ADAS-cog13, longitudinal analysis, the minimal model included years of
education, gender and APOE-e4 allele. For the longitudinal analysis with RAVLT,
the minimal model included years of education and gender.
Cox proportional hazards model was used to assess the impact of CSF analytes
on the time to AD conversion. The initial model contained age at baseline, gender,
years of education and APOE-e4 genotype as confounding variables together with
CSF ApoE, tau/Ab1–42 and ferritin. A minimal model containing only the CSF
biomarkers was identified via BIC step down procedure and log likelihood test.
Logistic regression analysis was used to assess the impact of CSF analytes on risk
of conversion to AD. Combinations of CSF ferritin, ApoE and tau/Ab1–42 analytes
were included in logistic regression models of MCI conversion to AD that were
adjusted for age at baseline, gender, years of education, APOE genotype and BMI.
These models determined the predictive performance of these analytes in identifying
stable MCI participants from MCI participants who, up to 102 months, had a
diagnosis change to AD. The receiver-operator curves and the area under the curve
were derived from the predictive probabilities of the logistic regression models.
The relationships between CSF ferritin, ApoE, tau/Ab1–42 with longitudinal
structural (MRI) changes to hippocampus and lateral ventricle were analysed using
linear mixed models adjusted for age, years of education, BMI, gender and APOE
genotype and intracranial volume. For all models, CSF ferritin, ApoE, tau/Ab1–42
and baseline diagnosis were included as fixed effects and were not removed from a
minimal model. Two random effects were also included, intercepts and slope
(time). An interaction between time and diagnosis, time and CSF ferritin, time and
CSF ApoE, as well as time and CSF tau/Ab1–42 were also included for all models.
All the AD subjects were excluded from MRI analyses due to low numbers and
short follow-up. PET imaging data from ADNI were not included in the analysis
because there were too few patients who had CSF ferritin measured and who also
underwent PET imaging at baseline.
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